Since NEO-201 target antigen is expressed both on solid tumors as well as in CD15+ granulocytes and regulatory T cells, we evaluated the reactivity of NEO-201 against hematological neoplastic cell lines in vitro, such as Acute Myeloid Leukemia (AML), Multiple Myeloma (MM), Acute Lymphoblastic Leukemia (ALL), Mantel Cell Lymphoma (MCL) cells in flow cytometry. The gene discussed is FUT4; the disease is acute myeloid leukemia.